Evidence map›Paper›PMID 28834075›Full record

SynthesisDiabetes, obesity & metabolism2018

Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review.

Kamlesh Khunti, Marilia B Gomes, Stuart Pocock, Marina V Shestakova, Stéphane Pintat, Peter Fenici, Niklas Hammar, Jesús Medina

Registry-linked trialAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetes, obesity & metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05535322. Cited by 182 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
182citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05535322 completed

Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity in the Department of Health of Valencia Clínico-Malvarrosa

Ran2014Enrolled26,944Registered outcomes12Posted comparisons0ConditionsObesity, Type 2 DiabetesArmsGLP-1RA, Insulin, Miscellany, SGLT2i
PMID 21457427PMID 29364585PMID 32347181PMID 32295809PMID 31673896PMID 31422062PMID 31028689PMID 30677504PMID 30291013PMID 29675797PMID 28801475PMID 28070733other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

182 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Evaluating Therapeutic Inertia in Two Telehealth Interventions for Type 2 Diabetes: Secondary Analyses of a Randomized Trial.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2024
    Trial
  12. Trial
  13. Trial
  14. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.The New England journal of medicine · 2022 · on this map
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

122 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kamlesh KhuntiUniversity of Leicester, Leicester, UK.ORCID 0000-0003-2343-7099
Marilia B GomesRio de Janeiro State University, Rio de Janeiro, Brazil.
Stuart PocockLondon School of Hygiene and Tropical Medicine, London, UK.
Marina V ShestakovaEndocrinology Research Center, Moscow, Russian Federation.
Stéphane PintatOxford PharmaGenesis, Oxford, UK.
Peter FeniciAstraZeneca, Cambridge, UK.
Niklas HammarAstraZeneca, Mölndal, Sweden.
Jesús MedinaAstraZeneca, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTherapeutic inertia, defined as the failure to initiate or intensify therapy in a timely manner according to evidence-based clinical guidelines, is a key reason for uncontrolled hyperglycaemia in patients with type 2 diabetes. The aims of this systematic review were to identify how therapeutic inertia in the management of hyperglycaemia was measured and to assess its extent over the past decade. MATERIALS AND

methodsSystematic searches for articles published from January 1, 2004 to August 1, 2016 were conducted in MEDLINE and Embase. Two researchers independently screened all of the titles and abstracts, and the full texts of publications deemed relevant. Data were extracted by a single researcher using a standardized data extraction form.

resultsThe final selection for the review included 53 articles. Measurements used to assess therapeutic inertia varied across studies, making comparisons difficult. Data from low- to middle-income countries were scarce. In most studies, the median time to treatment intensification after a glycated haemoglobin (HbA1c) measurement above target was more than 1 year (range 0.3 to >7.2 years). Therapeutic inertia increased as the number of antidiabetic drugs rose and decreased with increasing HbA1c levels. Data were mainly available from Western countries. Diversity of inertia measures precluded meta-analysis.

conclusionsTherapeutic inertia in the management of hyperglycaemia in patients with type 2 diabetes is a major concern. This is well documented in Western countries, but corresponding data are urgently needed in low- and middle-income countries, in view of their high prevalence of type 2 diabetes.

Indexed as

Evidence-Based MedicinePractice Patterns, Physicians'Combined Modality TherapyDiabetes Mellitus, Type 2Diet, DiabeticDrug MonitoringExerciseGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsTerminology as TopicGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic Agentsantidiabetic drugglycaemic controlsystematic reviewtype 2 diabetes

Identifiers

PMID28834075
PMCPMC5813232

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.